Free and total reduced concentrations of D-penicillamine have been measured in the plasma of rheumatoid arthritis patients by HPLC and electrochemical detection. A reverse-phase ion-pair separation in conjunction with a dual porous graphite electrode satisfied the requirements of robustness, sensitivity, selectivity and suitable retention time. Plasma levels measured between 1·5 and 3 h after an oral dose, were <0·3 to 57·6 umol/L and 0·6 to 85·0 umol/l, (n=26) for free and total reduced drug concentrations, respectively. Sources of error in the accurate measurement of peak plasma D-penicillamine levels were identified as oxidative loss and alteration in the free to protein-bound ratio in the period following sample collection.
The diverse therapeutic applications of Dpenicillamine, since its introduction as an effective treatment for Wilson's disease in 1953,I are well-documented.f In more recent times the compound has been used as a second line drug in the treatment of rheumatoid arthritis. ' It is recommended that the blood and urine of patients taking D-penicillamine should be monitored frequently during treatment to provide early detection of side effects which include dermatological, haematological and renal disorders." 5 The lack of guidance available on an effective plasma therapeutic range reflects the difficulty in establishing a reliable method of measurement in the clinical laboratory and the paucity of information on the plasma form(s) of Dpenicillamine responsible for effective clinical response.
Following oral ingestion, D-penicillamine is detectable in plasma in the native thiol configuration as free and protein bound forms and also in oxidised forms as penicillamine disulphide, free penicillamine-cysteine disulphide and the bound disulphide with protein cysteine groups." The hepatic metabolites Nacetylpenicillamine and S-methylpenicillamine have also been detected in the blood.": l! Methods based on HPLC and electrochemical detection for measurement of plasma 186 D-penicillamine have used gold,'} gold! mercury!" or glassy carbon!' electrodes.
We initiated an investigation of the correlation of plasma D-penicillamine levels with drug efficacy and toxicity by measuring concentrations of plasma reduced D-penicillamine in rheumatoid arthritis patients, using a HPLC system incorporating a coulometric dual porous graphite electrode detector.
Materials and methods

REAGENTS
D-penicillamine and p-aminobenzoic acid were obtained from Sigma Chemical Company, Poole, Dorset, UK. Sodium dodecyl sulphate ('Primar' grade) was obtained from Fisons Ltd, Loughborough, Leics, UK. HPLC-grade methanol was obtained from Rathburn Chemicals Ltd, Walkerburn, Scotland. Trichloroacetic acid ('Aristar' grade) and all other chemicals (rAnalar' grade) were obtained from BDH Chemicals Ltd, Poole, Dorset, UK. Water was doubly distilled before use.
STANDARDS
Stock D-penicillamine (2 mmol/L) was made up in water and diluted in mobile phase to give standard concentrations between 5 and 80 umol/L. To each standard (0,5 mL) was added 2l)%TCA (0·1 mL) and p-aminobenzoic acid as internal standard to S umol/L. After filtration through a 0·2 !J. filter (Acrodisc, Gelman) the solution was injected into the HPLC system. Stock standard was made up freshly each day and kept at 4°C.
SAMPLE PREPARATION
Out-patients with rheumatoid arthritis who had been taking D-penicillamine for at least 6 months were the subjects of this study. The routine oral dose of D-penicillamine was selfadministered immediately before breakfast and blood samples collected by forearm venepuncture into 5·l) mL EDTA vacutainer tubes (Becton Dickinson Type 6452) between 1·5 and 3 h later. Tubes were centrifuged (SOl) gX5 min) to separate plasma and cells. Sample treatment procedures were started within 30 min of sample collection.
CHROMATOGRAPHY
The HPLC technique used was a reverse-phase ion-pair method II modified by the omission of EDTA from the mobile phase.
Chromatography was carried out on a 25 cm Spherisorb amino 5 micron column (Jones Chromatography, Glamorgan, UK) thermostatted at 25°C. Samples were introduced via an injection valve with a 50 !J.L loop. A solvent metering pump (Beckman model I lOA) fitted with a pressure filter (Model 110-40 Altex) was used to deliver mobile phase through the system at a flow rate of 2·0 mUmin. Electrochemical detection was achieved with a type 5100A ESA electrochemical detector equipped with a model SOlO dual porous graphite electrode. Electrode I was set at 0·0 V and electrode 2 at +O·S V for thiol detection.
The electrode was protected from cloggingby inclusion of an in-line graphite filter and adequate filtration of the mobile phase through a 0·2 !J. membrane filter before use (Aero 50A, Gelman).
FREE I)-PENICILLAMINE MEASUREMENT
Plasma samples (1·0 mL) were ultrafiltered by centrifugation (2000gx20 min) at ISoC through a membrane filter (Centrifree MPS, Amicon). To the ultrafiltrate (0·2 mL) was added 20% TCA (0·05 ml.), internal standard to S umol/L and mobile phase to a final volume of ().) mL.
TOTAl. REDUCED I)-PENICILLAMINE
MEASUREMENT
This fraction includes free D-penicillamine and
Plasma Ir-peniciilamine 187 D-penicillamine non-covalently bound to proteins. Plasma (1·0 mL) was vortex mixed with 20% TCA (0·2 mL). After IS min at room temperature, precipitated protein was removed by centrifugation (800 gX5 min). The supernatant fraction was filtered and internal standard added to 8 umol/L concentration.
Acidified preparations for free and total reduced D-penicillamine analysis were stored for up to 6 h at 4°C prior to measurement.
STABILITY STUDIES
Several blood samples were collected 2·5 h after an oral dose of D-penicillamine. One was processed immediately, as described above, to give 'zero time' points for free and total reduced D-penicillamine concentrations. The remaining samples were kept at room temperature or on ice-water (as indicated in the text) and further samples processed at 30 and 60 min intervals.
Results
The elution profiles shown in Figs la and Ib demonstrate the electroactive components typically detected in TCA-treated plasma and plasma ultrafiltrates with the electrode set at an oxidising potential. D-penicillamine eluted as a single peak with a retention time of 6·0 min. The minimum detectable level under the operating conditions used was 0·3 J,&mol/L. The internal standard, p-aminobenzoic acid, eluted with a retention time of 7·3 min. Unidentified plasma components are responsible for the minor electroactive peak at 8 min and the major electroactive peak at II min. These compounds appear in equal amounts in ultrafiltrate and TCA-treated plasma indicating they are not bound to protein. Glutathione (Rt=2·1 min) and cysteine (Rt=2·6 min) are shown in Fig. 1c to be well separated from the D-penicillamine peak. In practice free endogenous glutathione and the penicillamine metabolite, Nacetylpenicillamine, elute with identical retention times as part of the large frontal peak. Homocysteine (Rt=5·4 min) is detected as a small peak adequately separated from Dpenicillamine.
The relationship between plasma Dpenicillamine concentration and oral dose is shown in Fig. 2 for both free and total reduced drug concentrations. Free penicillamine concentrations, expressed as a percentage of total reduced levels, ranged from 6·9 to 78·6%. 
D-penicillamine was as high as I mmol/L.
Recovery experiments were carried out by adding D-penicillamine to patients' plasma to two different concentrations and processing the sample as outlined in the Methods section (Table 1) . Changes in the concentration of free and total reduced D-penicillamine with time, following sample collection, arc shown in Fig. 3 . Total reduced drug concentrations were found to decline by up to 30'X. of decrease was reduced by storing samples at (rc. Changes in free D-penicillamine at room temperature in the same samples did not follow this pattern. In four out of the five patients studied, free D-penicillamine increased over the first 30 min and then began to decrease. Where patients' blood samples were stored at ere (two cases) this increase in free Dpenicillamine was significantly greater and still rising after 60 min. These changes in concentration of free and total reduced D-penicillamine were similar whether the samples were stored as whole blood or separated plasma.
Discussion
The decision to measure reduced forms of Dpenicillamine in this study was influenced by two factors. First the native thiol form of the drug is chemically more reactive than its oxidation products and so may be expected to be the structure with greater potential for pharmacological and toxicological activity. Secondly, it has been shown by others12 that after oral administration of D-penicillaminc the change with time of plasma total reduced drug concentration follows a typical absorption curve, peaking within 1-4 h.
The measurement of total D-penicillamine was not attempted, as a simple procedure for Plasma D-penicillamine 189 the quantitative reduction of the oxidised forms of the drug is unavailable. 13 The HPLC method gave a precise reproducible method with adequate separation of Dpenicillamine from endogenous electroactive compounds in plasma. EDTA was omitted from the mobile phase described in the original methodII since its inclusion resulted in an erratic baseline trace when using the porous carbon electrode as detector. Under the separation conditions of low pH and temperature, penicillamine loss due to oxidation on the column can be assumed to be negligible, making the inclusion of EDTA in the buffer unnecessary. Peak splitting, that has been described in HPLC analysis of D-penicillamine, did not occur in this method as evidenced by the reproducible electroactive pattern of standards and the high yield of total D-penicillamine in recovery experiments.
The dual porous carbon electrode proved to . be robust and gave reproducible traces for plasma samples over several months with a minimum of maintenance.
The stability of plasma D-penicillamine in the period immediately following blood sampling was investigated for two main reasons. Firstly, it is necessary to know how long processing of samples can be delayed before significant oxidative losses of D-penicillamine occur. Secondly, results that have been published on D-penicillamine stability following addition to albumin solution or plasma, 14 . IS are not directly comparable to stability studies carried out on patients' samples. In the albumin study, Dpenicillamine would be rapidly lost by thiolprotein disulphide exchange. The proteins in patients' plasma, however, will have been exposed to D-penicillamine for several weeks leaving far fewer disulphide links for exchange and implicating oxidation as the main factor responsible for losses. The rapid formation of disulphide links between D-penicillamine and serum proteins explains the failure to recover D-penicillamine added to a drug-free serum pool as previously indicated in the results section. Thiol-disulphide exchange, by lowering available levels of reduced D-penicillamine, might also be a factor in determining the initial period of several weeks that patients require to take the drug before remission of symptoms is likely to occur. Following the equilibration period, the plasma concentration of free Dpenicillamine might be expected to provide the best indication of clinical response, but in this limited study we were unable to find any simple correlation between free or total reduced drug concentrations and efficacy.
The time-plasma concentration curves obtained by Butler et al. 12 revealed that the peak plasma concentration of D-penicillamine may be reached at any point between I and 4 h after an oral dose and that this level is maintained for a relatively short period, approximately 0·5 h. Taking blood samples at a random time between 1·5 and 3 h, as in the current study, can lead to a reduction in the true peak value of up to 52%. When this sampling error is combined with the error due to oxidative loss in the 60 min following sample collection the negative bias from the true peak value could approach 90%. Sensitivity of the method precluded measurement of trough concentrations.
A comparison of these results with published ranges for plasma total reduced Dpenicillamine concentrations shows that our findings compare favourably with values of 4·8 to 18·7 umol/L given by Russell et al.:() although ours was based on a larger population sample. A mean concentration for total reduced D-penicillamine of 16·7 umol/L given by Shaw et al, 17 for samples removed between 8 and 9 h after a dose of 125 mg would appear high on comparison with other published data. In Jefferies' study11 values of 7 to 78ltmoVL for plasma total reduced D-penicillamine and 0 to 1 umol/L for free D-penicillamine were obtained on samples taken at random times after dose ingestion. The concentrations quoted for total reduced D-penicillamine included that released by reduction of disulphide bonds.
Although free and total reduced concentrations of D-penicillamine obtained in this study correlated approximately with dosage the accuracy with which measurement can be made is reduced by the following factors. Oxidative loss occurring after sample collection will lower total reduced and free drug concentrations, but have more effect on free drug concentrations due to the longer processing time required to produce the ultrafiltrate. Changes in bound to free equilibrium will result in measured free concentrations of the drug being a resultant of an increase due to the change in this equilibrium and oxidative loss. Inter-patient variability in dose to peak time will affect both free and total reduced D-penicillamine fractions.
These potential measurement errors are not easily eliminated and in conjunction with interpatient variability in pharmacokinetic uptake and elimination rates, will be expected to contribute to the wide scatter of plasma concentrations observed for individual doses of Dpenicillamine.
